Strongly ROS-Correlated, Time-Dependent, and Selective Antiproliferative Effects of Synthesized Nano Vesicles on BRAF

Silvana Alfei1, Guendalina Zuccari1,2, Constantinos M Athanassopoulos3

  • 1Department of Pharmacy, University of Genoa, Viale Cembrano, 16148 Genoa, Italy.

Insights

Triphenyl phosphonium salts (TPPSs) show potent anticancer effects against cutaneous metastatic melanoma (CMM) by targeting mitochondria. A novel TPP-based bola amphiphile (BPPB) formulated in a hyaluronic acid hydrogel offers a promising topical treatment for CMM.

Area of Science:

  • Biochemistry
  • Materials Science
  • Oncology

Background:

  • Cutaneous metastatic melanoma (CMM) is an aggressive skin cancer with poor prognosis.
  • Drug resistance and secondary tumorigenesis necessitate novel therapeutic strategies.
  • Triphenyl phosphonium salts (TPPSs) target mitochondria, inducing cell death and oxidative stress.

Purpose of the Study:

  • To investigate the efficacy of a TPP-based bola amphiphile (BPPB) against CMM cell lines.
  • To evaluate the potential of BPPB as a topical treatment for CMM.
  • To develop a safe and effective hydrogel formulation for BPPB delivery.

Main Methods:

  • Investigated BPPB effects on BRAF-mutant CMM cell lines (MeOV, MeTRAV).
  • Assessed BPPB cytotoxicity against non-tumoral cell lines and red blood cells (RBCs).
  • Formulated a hyaluronic acid (HA)-based hydrogel (HA-BPPB-HG) for BPPB delivery.

Main Results:

  • BPPB demonstrated excellent anticancer activity against CMM cells, with IC50 values as low as 49 nM.
  • BPPB exhibited low cytotoxicity towards non-tumoral cells and RBCs, indicating high selectivity (selectivity index up to 299).
  • The HA-BPPB-HG formulation showed promising characteristics, including high swelling, porosity, and suitable rheological behavior.

Conclusions:

  • BPPB is a potent agent against CMM, targeting mitochondria and exhibiting high selectivity.
  • The HA-BPPB-HG hydrogel offers a viable platform for topical CMM treatment.
  • Further development of BPPB holds promise for a new therapeutic approach to CMM.